NDA 210797 · Clivunel INC
Scenesse
Afamelanotide · Subcutaneous
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Oct 8, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
22
6 Phase 3, 0 recruiting
FAERS reports
21
17 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 11, 2026.
SCENESSE ® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). SCENESSE is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 8, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- SCENESSE · AFAMELANOTIDE 16MG · IMPLANT, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Afamelanotide" as an intervention, any sponsor and status, largest first.
- Phase II AK Study in Organ Transplant PatientsPivotal-lookingStatus unknown
Clinuvel Pharmaceuticals LimitedIndustry
NCT00829192 · 200 participants (planned) · Start Nov 2007 · Primary completion Jul 2012
Drug: Afamelanotide (CUV1647); Placebo · For: Actinic Keratoses; Carcinoma, Squamous Cell; Organ Transplant Recipients
Sites: Brisbane, Australia; Adelaide, Australia; Melbourne, Australia · 12 sites in all
- A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With VitiligoPivotal-lookingActive, not recruiting
Clinuvel, Inc.Industry
NCT06109649 · 200 participants (planned) · Start Oct 11, 2023 · Primary completion Dec 2025
Drug: Afamelanotide and NB-UVB Light · For: Vitiligo
Sites: Birmingham, Alabama; Fresno, California; Los Angeles, California · 30 sites in all
- Multicentre Phase III Erythropoietic Protoporphyria StudyPivotal-lookingCompleted
Clinuvel Pharmaceuticals LimitedIndustry
NCT04053270 · 100 participants · Start May 2007 · Primary completion Dec 9, 2009
Drug: Afamelanotide; Placebo · For: Erythropoietic Protoporphyria
- Phase III Confirmatory Study in Erythropoietic ProtoporphyriaPivotal-lookingCompleted
Clinuvel Pharmaceuticals LimitedIndustry
NCT01605136 · 93 participants · Start May 2012 · Primary completion Jul 2013
Drug: Afamelanotide; Placebo · For: Erythropoietic Protoporphyria
Sites: Birmingham, Alabama; San Francisco, California; Detroit, Michigan · 7 sites in all
Clinuvel Pharmaceuticals LimitedIndustry
NCT01097044 · 77 participants · Start Apr 2010 · Primary completion Apr 2011
Drug: Afamelanotide; Placebo · For: Erythropoietic Protoporphyria
Sites: Birmingham, Alabama; San Francisco, California; New York, New York · 6 sites in all
- Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)Pivotal-lookingCompleted
Clinuvel Pharmaceuticals LimitedIndustry
NCT00979745 · 74 participants · Start Sep 2009 · Primary completion May 2011
Drug: Afamelanotide; Placebo · For: Erythropoietic Protoporphyria
Sites: Helsinki, Finland; Colombes, France; Düsseldorf, Germany · 8 sites in all
Clinuvel Pharmaceuticals LimitedIndustry
NCT01430195 · 56 participants · Start Jun 2011 · Primary completion May 2012
Drug: Afamelanotide · For: Vitiligo
Sites: Detroit, Michigan; New York, New York
- Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)Pivotal-lookingCompleted
Clinuvel Pharmaceuticals LimitedIndustry
NCT04704713 · 31 participants · Start May 5, 2010 · Primary completion Dec 9, 2010
Drug: Afamelanotide; Placebo · For: Polymorphic Light Eruption
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anaphylactic reaction4
- contraindication to medical treatment3
- type i hypersensitivity3
- implant site hypersensitivity2
- implant site pruritus2
- implant site urticaria2
- malignant melanoma2
- vomiting2
- acute kidney injury1
- acute on chronic liver failure1
- appendicitis1
- ascites1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Afamelanotide for Erythropoietic Protoporphyria.
Langendonk JG, Balwani M, Anderson KE, et al. · N Engl J Med 2015 · Multicenter Study, Randomized Controlled Trial
- Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease.
Biolcati G, Aurizi C, Barbieri L, et al. · Clin Exp Dermatol 2014 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH.
Haylett AK, Nie Z, Brownrigg M, et al. · Br J Dermatol 2011 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Beneficial effects of the melanocortin analogue Nle4-D-Phe7-α-MSH in acne vulgaris.
Böhm M, Ehrchen J, Luger TA · J Eur Acad Dermatol Venereol 2014 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone.
Harms JH, Lautenschlager S, Minder CE, et al. · Photochem Photobiol 2009 · Clinical Trial, Research Support, Non-U.S. Gov't
- Adjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study.
Shetty N, Quiñonez RL, Ceresnie MS, et al. · Photochem Photobiol 2026 · Clinical Trial, Letter
Sponsor: Clivunel INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.